ANDA 202586, held by Bwxt Itg. Indium In-111 Oxyquinoline.
As of Nov 16, 2026, ANDA 202586 (Indium In 111 Oxyquinoline), held by Bwxt Itg, was first approved by FDA on Jul 25, 2018, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Indium In 111 oxyquinoline is indicated for radiolabeling autologous leukocytes. Indium In 111 oxyquinoline labeled leukocytes may be used as an adjunct in the detection of inflammatory processes to which leukocytes migrate, such as those associated with abscesses or other infection, following reinjection and detection by appropriate imaging procedures. The degree of accuracy may vary with labeling techniques and with the size, location and nature of the inflammatory process. Indium In 111 oxyquinoline labeled leukocyte imaging is not the preferred technique for the initial evaluation of patients with a high clinical probability of an abscess in a known location.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 25, 2018 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Indium In 111 Oxyquinoline1mCi/ML · injectable;injection | Indium In-111 Oxyquinoline | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters